NEU1 sirna

NEU1 siRNA (Human)

Cat. Num. AAA8208531

• Gene Names: NEU1; NEU; NANH; SIAL1
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: NEU1; NEU1 siRNA (Human); NANH; Sialidase-1; Acetylneuraminyl hydrolase; G9 sialidase; Lysosomal sialidase; N-acetyl-alpha-neuraminidase 1; NEU1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: NEU1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 415

• Applicable Applications for NEU1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human NEU1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for NEU1 sirna

siRNA to inhibit NEU1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4557791
• NCBI GeneID: 4758
• NCBI Accession #: NP_000425.1
• NCBI GenBank Nucleotide #: NM_000434.3
• UniProt Accession #: Q99519
• Molecular Weight: 45,467 Da
• NCBI Official Full Name: sialidase-1
• NCBI Official Synonym Full Names: sialidase 1 (lysosomal sialidase)
• NCBI Official Symbol: NEU1
• NCBI Official Synonym Symbols: NEU; NANH; SIAL1
• NCBI Protein Information: sialidase-1
• UniProt Protein Name: Sialidase-1
• Protein Family: Sialidase
• UniProt Gene Name: NEU1
• UniProt Synonym Gene Names: NANH
• UniProt Entry Name: NEUR1_HUMAN

NCBI Description

The protein encoded by this gene is a lysosomal enzyme that cleaves terminal sialic acid residues from substrates such as glycoproteins and glycolipids. In the lysosome, this enzyme is part of a heterotrimeric complex together with beta-galactosidase and cathepsin A (the latter is also referred to as 'protective protein'). Mutations in this gene can lead to sialidosis, a lysosomal storage disease that can be type 1 (cherry red spot-myoclonus syndrome or normosomatic type), which is late-onset, or type 2 (the dysmorphic type), which occurs at an earlier age with increased severity. [provided by RefSeq, Jul 2008]

Uniprot Description

NEU1: Catalyzes the removal of sialic acid (N-acetylneuramic acid) moities from glycoproteins and glycolipids. To be active, it is strictly dependent on its presence in the multienzyme complex. Appears to have a preference for alpha 2-3 and alpha 2-6 sialyl linkage. Defects in NEU1 are the cause of sialidosis (SIALIDOSIS). It is a lysosomal storage disease occurring as two types with various manifestations. Type 1 sialidosis (cherry red spot-myoclonus syndrome or normosomatic type) is late-onset and it is characterized by the formation of cherry red macular spots in childhood, progressive debilitating myoclonus, insiduous visual loss and rarely ataxia. The diagnosis can be confirmed by the screening of the urine for sialyloligosaccharides. Type 2 sialidosis (also known as dysmorphic type) occurs as several variants of increasing severity with earlier age of onset. It is characterized by the presence of abnormal somatic features including coarse facies and dysostosis multiplex, vertebral deformities, mental retardation, cherry-red spot/myoclonus, sialuria, cytoplasmic vacuolation of peripheral lymphocytes, bone marrow cells and conjunctival epithelial cells. Belongs to the glycosyl hydrolase 33 family.

Protein type: Hydrolase; EC 3.2.1.18; Lipid Metabolism - sphingolipid; Motility/polarity/chemotaxis; Glycan Metabolism - other glycan degradation

Chromosomal Location of Human Ortholog: 6p21.3

Cellular Component: cell junction; cell surface; cytoplasmic membrane-bound vesicle; intracellular membrane-bound organelle; lysosomal lumen; lysosomal membrane; lysosome; membrane; plasma membrane

Molecular Function: exo-alpha-sialidase activity

Biological Process: cellular protein metabolic process; dolichol-linked oligosaccharide biosynthetic process; ganglioside catabolic process; glycosphingolipid metabolic process; oligosaccharide catabolic process; post-translational protein modification; protein amino acid N-linked glycosylation via asparagine; sphingolipid metabolic process

Disease: Neuraminidase Deficiency